Patterns of drug resistance and RFLP analysis of Mycobacterium tuberculosis strains isolated from recurrent tuberculosis patients in Sri Lanka

Southeast Asian Journal of Tropical Medicine and Public Health

Volumn 41, Issue 3, 2010, Pages 583-589

  Magana Arachchi, D N ^a   Perera, A J ^a   Senaratne, V ^b   Chandrasekharan, N V ^c  

^a Faculty of Medicine   (Sri Lanka)

^b Central Chest Hospital   (Sri Lanka)

^c UNIVERSITY OF COLOMBO   (Sri Lanka)

Author keywords

Drug resistant patterns; Mycobacterium tuberculosis; Recurrent TB patients; RFLP analysis; Sri lanka

Indexed keywords

ANTIBIOTIC RESISTANCE; ARTICLE; CLASSIFICATION; DRUG EFFECT; HUMAN; LUNG TUBERCULOSIS; MICROBIOLOGICAL EXAMINATION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; RECURRENT DISEASE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SRI LANKA;

DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RECURRENCE; SRI LANKA; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 77954699842     PISSN: 01251562     EISSN: 26975718     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Bauer J, Andersen AB, Kremer K, Miorner H. Usefulness of spoligotyping to discriminate IS 6110 low copy number Mycobacterium tuberculosis complex strains cultured in Denmark. J Clin Microbiol 1999; 37: 2602-6.
2. Bloch AB, Cauthen GM, Onorato IM, et al. Nationwide survey of drug-resistant tuberculosis in the United States. JAMA 1994; 271: 665-71.
3. Cavusoglu C, Karaca-Derici Y, Bilgic A. In-vitro activity of rifabutin against rifampicin resistant Mycobacterium tuberculosis isolates with known rpo B mutations. Clin Microbiol Infect 2004; 10: 662-5.
4. Centers for Disease Control. Emergence of Mycobacterium tuberculosis with extensive resistance to second line drugs worldwide, 2000-2004. Morbid Mortal Weekly Rep (MMWR) 2006; 55: 301-5.
5. Croffton J, Chaulet P, Maher D. Guidelines for the management of drug resistant tuberculosis. Geneva: WHO, 1997.
6. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as acause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368: 1575-80.
7. Gillespie SH, Dickens A, McHugh TD. False molecular clusters due to non - random association of IS6110 with Mycobacterium tuberculosis. J Clin Microbiol 2000; 38:2081-6.
8. Kubica GP, Dye WE, Cohn ML, et al. Sputum digestion and decontamination with N-acetyl L-cysteine as a sputum digestant for the isolation of mycobacteria. Am Rev Respir Dis 1963; 89: 284-6.
9. Mathema B, Kurepina NE, Bifani PJ, et al. Molecular epidemiology of tuberculosis:current insights. Clin Microbiol Rev 2006; 19: 658-85.
10. Mitike G, Kebede D, Yeneneh H. Prevalence of antituberculosis drug resistance in Harar Tuberculosis Centre, Ethiopia. East Afr Med J 1997; 74: 158-61.
11. Razanamparany VR, Ramarokoto HH, Vololonirina EJ, et al. RFLP clusters of Mycobacterium tuberculosis strains from the Indian Ocean Region: local and South Asian characteristics. Mem Inst Oswaldo Cruz 2009; 104: 441-3.
12. Ridzon R, Whitney CG, McKenna MT, et al. Risk factors for rifampin mono-resistant tuberculosis. Am J Respir Crit Care Med 1998; 157: 1881-4.
13. Samper S, Martin C. Spread of extensively drug-resistant tuberculosis. Emerg Infect Dis 2007; 13: 647-8.
14. Saravia JC, Appleton SC, Rich ML, Sarria M, Bayona J, Becerra MC. Retreatment management strategies when first-line tuberculosis therapy fails. Int J Tuberc Lung Dis 2005; 9: 421-9.
15. van Embden JD, Cave MD, Crawford JT, et al. Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J Clin Microbiol 1993; 31: 406-9.
16. van Soolingen D, de Haas PE, Hermans PW,Groenen PM, van Embden JD. Comparison of various repetitive DNA elements as genetic markers for strain differentiation and epidemiology of M.tuberculosis. J Clin Microbiol 1993; 31: 1987-95.
17. World Health Organization. Global tuberculosis control: surveillance, planning, financing. WHO report 2007. WHO/HTM/TB/2007.376. 2007.